| Serial Number | 88308511 |
| Word Mark | PAIGE |
| Filing Date | Wednesday, February 20, 2019 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, November 24, 2020 |
| Registration Number | 6206397 |
| Registration Date | Tuesday, November 24, 2020 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 2, 2019 |
| Goods and Services | Medical services; cancer therapy services; medical testing, namely, the review and analysis of patients' clinical slides to identify additional recommended medical testing; medical testing for the diagnosis of diseases, states, or conditions; medical testing for evaluation of prognosis relating to diseases, states, or conditions; medical testing for the monitoring of diseases, states, or conditions; medical testing to detect or identify predispositions to diseases, states, or conditions; medical testing to detect or determine the recurrence of diseases, states, or conditions; medical testing to detect, monitor, or evaluate responses to treatment of diseases, states, or conditions; medical testing to evaluate clinical management of diseases, states, or conditions; medical testing for selection of treatment for diseases, states, or conditions; medical testing to evaluate or facilitate prevention of diseases, states, or conditions; medical testing to select, facilitate, monitor, or evaluate palliation or treatment of diseases, states or conditions; medical testing in the field of cancer; medical testing in the field of oncology; medical diagnostic testing, monitoring, or reporting services; medical analysis or advisory services in the field of cancer; medical analysis or advisory services in the field of oncology; medical analysis or advisory services for medical treatment; medical analysis or advisory services for the diagnosis of diseases, states, or conditions; medical analysis or advisory services for the evaluation of prognosis relating to diseases, states, or conditions; medical analysis or advisory services relating to monitoring diseases, states, or conditions; medical analysis or advisory services relating to the detection or identification of predispositions to diseases, states, or conditions; medical analysis or advisory services relating to the detection or determination of the recurrence of diseases, states, or conditions; medical analysis or advisory services relating to the detection, monitoring, or evaluation of responses to treatment of diseases, states, or conditions; medical analysis or advisory services relating to the clinical management of diseases, states, or conditions; medical analysis or advisory services relating to the selection of treatment for diseases, states, or conditions; medical analysis or advisory services relating to the prevention of diseases, states, or conditions; medical analysis or advisory services relating to the palliation or treatment of diseases, states or conditions; qualitative image analysis in the field of digital pathology for medical purposes; quantitative image analysis in the field of digital pathology for medical purposes; providing non-research related medical information via the internet; medical analysis services for the diagnosis of cancer by reviewing pathological samples on slides |
| Goods and Services | Software as a service (SaaS) services featuring software for artificial intelligence, machine learning, deep learning, statistical learning, data mining, and contextual prediction; software as a service (SaaS) services featuring software for use in disease pathology, namely, software that reads digital slides and provides diagnoses; software as a service (SaaS) services featuring software for use in diagnosis of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in evaluation of prognosis relating to diseases, states, or conditions; software as a service (SaaS) services featuring software for use in monitoring of diseases, states, or conditions; software as a service (SaaS) services featuring software for use to detect or identify predispositions to diseases, states, or conditions; software as a service (SaaS) services featuring software to detect the recurrence of diseases, states, or conditions; software as a service (SaaS) services featuring software to detect, monitor, or evaluate patients' responses to treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in clinical management of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in the selection of treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in prevention of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in palliation or treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in research or development in the field of life sciences; software as a service (SaaS) services featuring software for use in research or development in the field of medicine; software as a service (SaaS) services featuring software for use in research or development in the field of healthcare; software as a service (SaaS) services featuring software for use in research or development in the field of cancer; software as a service (SaaS) services featuring software for use in research or development in the field of oncology; software as a service (SaaS) services featuring software for use in research or development in the field of pathology; design and development of AI-powered computer software that analyzes clinical pathology slides and diagnoses diseases; medical research; scientific research and development services in the field of pathology; research and development services in the field of medicine; research and development services in the field of cancer; research and development services in the field of healthcare; research and development services in the field of life sciences; research and development services in the field of oncology; medical and scientific research services in the field of pathology; medical and scientific research services in the field of cancer; medical and scientific research services in the field of healthcare; medical and scientific research services in the field of life sciences; medical and scientific research services in the field of oncology; research and development of technology in the field of pathology; research and development of technology in the field of medicine; research and development of technology in the field of cancer; research and development of technology in the field of healthcare; research and development of technology in the field of life sciences; research and development of technology in the field of oncology; providing medical research and scientific research information via the internet; electronic scanning of clinical pathology slides; software as a service services (SaaS) featuring software for use in the analysis of clinical pathology slides; medical and scientific testing services for research purposes |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, March 12, 2019 |
| Primary Code | 042 |
| First Use Anywhere Date | Thursday, February 21, 2019 |
| First Use In Commerce Date | Thursday, February 21, 2019 |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, March 12, 2019 |
| Primary Code | 044 |
| First Use Anywhere Date | Thursday, February 21, 2019 |
| First Use In Commerce Date | Thursday, February 21, 2019 |
| Party Name | PAIGE.AI, Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10036 |
| Party Name | PAIGE.AI, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10044 |
| Party Name | PAIGE.AI, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10044 |
| Event Date | Event Description |
| Friday, January 29, 2021 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Friday, January 29, 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, January 29, 2021 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, January 29, 2021 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, January 29, 2021 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, November 24, 2020 | REGISTERED-PRINCIPAL REGISTER |
| Thursday, October 22, 2020 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Wednesday, October 21, 2020 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Wednesday, October 21, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, October 21, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, October 13, 2020 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, October 13, 2020 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, October 13, 2020 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, October 13, 2020 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, October 13, 2020 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, October 13, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, September 11, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, September 11, 2020 | NON-FINAL ACTION E-MAILED |
| Friday, September 11, 2020 | SU - NON-FINAL ACTION - WRITTEN |
| Thursday, August 13, 2020 | STATEMENT OF USE PROCESSING COMPLETE |
| Friday, July 31, 2020 | USE AMENDMENT FILED |
| Wednesday, August 12, 2020 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Friday, July 31, 2020 | TEAS STATEMENT OF USE RECEIVED |
| Wednesday, July 8, 2020 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, July 8, 2020 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, July 8, 2020 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, July 8, 2020 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, July 8, 2020 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, April 24, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, April 22, 2020 | EXTENSION 1 GRANTED |
| Wednesday, April 22, 2020 | EXTENSION 1 FILED |
| Wednesday, April 22, 2020 | TEAS EXTENSION RECEIVED |
| Tuesday, October 22, 2019 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, September 11, 2019 | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED |
| Wednesday, August 14, 2019 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, August 14, 2019 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, July 31, 2019 | EXTENSION OF TIME TO OPPOSE RECEIVED |
| Tuesday, July 2, 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 2, 2019 | PUBLISHED FOR OPPOSITION |
| Wednesday, June 12, 2019 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, May 29, 2019 | ASSIGNED TO LIE |
| Wednesday, May 15, 2019 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, May 15, 2019 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, May 15, 2019 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, May 15, 2019 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, May 15, 2019 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, May 1, 2019 | ASSIGNED TO EXAMINER |
| Tuesday, March 12, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Saturday, February 23, 2019 | NEW APPLICATION ENTERED IN TRAM |